Galactose epimerase deficiency: lessons from the GalNet registry.

Galactose epimerase deficiency Galactose-restricted diet Galactosemia type III Galactosemias Network

Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
02 09 2022
Historique:
received: 24 05 2022
accepted: 15 08 2022
entrez: 2 9 2022
pubmed: 3 9 2022
medline: 9 9 2022
Statut: epublish

Résumé

Galactose epimerase (GALE) deficiency is a rare hereditary disorder of galactose metabolism with only a few cases described in the literature. This study aims to present the data of patients with GALE deficiency from different countries included through the Galactosemia Network to further expand the existing knowledge and review the current diagnostic strategy, treatment and follow-up of this not well characterized entity. Observational study collecting medical data from December 2014 to April 2022 of 22 not previously reported patients from 14 centers in 9 countries. Patients were classified as generalized or non-generalized based on their genotype, enzyme activities in different tissues and/or clinical picture and professional judgment of the treating physician. In total 6 patients were classified as generalized and 16 as non-generalized. In the generalized group, acute neonatal illness was reported in 3, cognitive and developmental delays were present in 5 and hearing problems were reported in 3. Four generalized patients were homozygous for the genetic variant NM_001008216.2:c.280G > A (p.Val94Met). In the non-generalized group, no clearly related symptoms were found. Ten novel genetic variants were reported in this study population. The phenotypic spectrum of GALE deficiency ranges from asymptomatic to severe. The generalized patients have a phenotype that is in line with the 9 described cases in the literature and prescribing dietary interventions is the cornerstone for treatment. In the non-generalized group, treatment advice is more difficult. To be able to offer proper counseling, in addition to red blood cell enzyme activity, genetic studies, transferrin glycoform analysis and enzymatic measurements in fibroblasts are recommended. Due to lack of facilities, additional enzymatic testing is not common practice in many centers nor a tailored long-term follow-up is performed.

Sections du résumé

BACKGROUND
Galactose epimerase (GALE) deficiency is a rare hereditary disorder of galactose metabolism with only a few cases described in the literature. This study aims to present the data of patients with GALE deficiency from different countries included through the Galactosemia Network to further expand the existing knowledge and review the current diagnostic strategy, treatment and follow-up of this not well characterized entity.
METHODS
Observational study collecting medical data from December 2014 to April 2022 of 22 not previously reported patients from 14 centers in 9 countries. Patients were classified as generalized or non-generalized based on their genotype, enzyme activities in different tissues and/or clinical picture and professional judgment of the treating physician.
RESULTS
In total 6 patients were classified as generalized and 16 as non-generalized. In the generalized group, acute neonatal illness was reported in 3, cognitive and developmental delays were present in 5 and hearing problems were reported in 3. Four generalized patients were homozygous for the genetic variant NM_001008216.2:c.280G > A (p.Val94Met). In the non-generalized group, no clearly related symptoms were found. Ten novel genetic variants were reported in this study population.
CONCLUSION
The phenotypic spectrum of GALE deficiency ranges from asymptomatic to severe. The generalized patients have a phenotype that is in line with the 9 described cases in the literature and prescribing dietary interventions is the cornerstone for treatment. In the non-generalized group, treatment advice is more difficult. To be able to offer proper counseling, in addition to red blood cell enzyme activity, genetic studies, transferrin glycoform analysis and enzymatic measurements in fibroblasts are recommended. Due to lack of facilities, additional enzymatic testing is not common practice in many centers nor a tailored long-term follow-up is performed.

Identifiants

pubmed: 36056436
doi: 10.1186/s13023-022-02494-4
pii: 10.1186/s13023-022-02494-4
pmc: PMC9438182
doi:

Substances chimiques

UDPglucose 4-Epimerase EC 5.1.3.2

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

331

Informations de copyright

© 2022. The Author(s).

Références

J Biol Chem. 2005 Apr 8;280(14):13493-502
pubmed: 15701638
Am J Hum Genet. 2006 Jan;78(1):89-102
pubmed: 16385452
J Inherit Metab Dis. 1998 Jun;21(4):341-50
pubmed: 9700591
J Inherit Metab Dis. 1988;11 Suppl 2:249-51
pubmed: 3141714
JIMD Rep. 2017;37:19-25
pubmed: 28247339
Proc Natl Acad Sci U S A. 1971 Nov;68(11):2660-3
pubmed: 4941982
Lancet. 1995 Oct 21;346(8982):1073-4
pubmed: 7564790
Glycobiology. 2005 Dec;15(12):1268-76
pubmed: 16037488
Arch Dis Child. 1981 Nov;56(11):885-7
pubmed: 7305435
Hum Mol Genet. 2019 Jan 1;28(1):133-142
pubmed: 30247636
Am Fam Physician. 2017 Jul 1;96(1):36-43
pubmed: 28671370
Pediatrics. 1994 Oct;94(4 Pt 1):558-65
pubmed: 7755691
Gene. 2013 Jul 25;524(2):95-104
pubmed: 23644136
Mol Genet Metab. 2005 Jan;84(1):32-8
pubmed: 15639193
JIMD Rep. 2012;2:113-7
pubmed: 23430863
Am J Med Genet A. 2021 Oct;185(10):3118-3121
pubmed: 34159722
Mol Syndromol. 2020 Dec;11(5-6):320-329
pubmed: 33510604
Helv Paediatr Acta. 1973 Dec;28(6):497-510
pubmed: 4785150
Orphanet J Rare Dis. 2019 Apr 27;14(1):86
pubmed: 31029175
J Pediatr. 1983 Dec;103(6):927-30
pubmed: 6549612
Glycobiology. 1998 Apr;8(4):351-7
pubmed: 9499382
Biochemistry. 2000 May 16;39(19):5691-701
pubmed: 10801319
J Inherit Metab Dis. 2017 Mar;40(2):169-170
pubmed: 27837294
Arch Dis Child. 1999 Apr;80(4):374-6
pubmed: 10086948
J Inherit Metab Dis. 1983;6(1):17-20
pubmed: 6408303
Am J Hum Genet. 1999 Feb;64(2):462-70
pubmed: 9973283
Indian J Pediatr. 2010 Aug;77(8):909-10
pubmed: 20725869
Gene. 2013 Sep 10;526(2):318-24
pubmed: 23732289
Helv Paediatr Acta. 1972 Jun;27(2):125-30
pubmed: 4644860
J Biol Chem. 2020 Jan 31;295(5):1225-1239
pubmed: 31819007
FEBS J. 2005 Dec;272(23):6170-7
pubmed: 16302980

Auteurs

Britt Derks (B)

Department of Pediatrics and Clinical Genetics, Maastricht University Medical Centre+, P. Debyelaan 25, P.O. Box 5800, 6229 HX, Maastricht, The Netherlands.
GROW, Maastricht University, Maastricht, The Netherlands.
MetabERN: European Reference Network for Hereditary Metabolic Disorders, Udine, Italy.
UMD: United for Metabolic Diseases Member, Amsterdam, The Netherlands.

Didem Demirbas (D)

Division of Genetics and Genomics, Harvard Medical School, Boston Children's Hospital, 3 Blackfan Circle, Center for Life Science Building, Suite 14070, Boston, MA, 02115, USA.

Rodrigo R Arantes (RR)

Special Service of Medical Genetics, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Samantha Banford (S)

South Eastern Health and Social Care Trust, Downpatrick, BT30 6RL, UK.

Alberto B Burlina (AB)

MetabERN: European Reference Network for Hereditary Metabolic Disorders, Udine, Italy.
Division of Inherited Metabolic Diseases, University Hospital, Via Orus 2/B, 35128, Padua, Italy.

Analía Cabrera (A)

Nutrition Department, Hospital de Niños V.J. Vilela, Sante Fe, Rosario, Argentina.

Ana Chiesa (A)

Department of Endocrinology, Hospital de Niños Ricardo Gutièrrez, Buenos Aires, Argentina.

M Luz Couce (ML)

MetabERN: European Reference Network for Hereditary Metabolic Disorders, Udine, Italy.
Metabolic Unit, IDIS, Department of Neonatology, University Clinical Hospital of Santiago de Compostela. Calle Choupana, s/n, 15706, Santiago de Compostela, Spain.

Carlo Dionisi-Vici (C)

MetabERN: European Reference Network for Hereditary Metabolic Disorders, Udine, Italy.
Division of Metabolism, Bambino Gesu Children's Research Hospital IRCCS, Piazza S Onofrio 4, 00165, Roma, Italy.

Matthias Gautschi (M)

Division of Paediatric Endocrinology and Metabolism, Department of Paediatrics, University Hospital Bern, Inselspital, Freiburgstrasse 15, CH-3010, Bern, Switzerland.

Stephanie Grünewald (S)

Metabolic Medicine Department, NIHR Biomedical Research Center (BRC), Institute for Child Health, Great Ormond Street Hospital, University College London, London, UK.

Eva Morava (E)

Department of Clinical Genomics and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Dorothea Möslinger (D)

Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Sabine Scholl-Bürgi (S)

MetabERN: European Reference Network for Hereditary Metabolic Disorders, Udine, Italy.
Clinic for Pediatrics I, Inherited Metabolic Disorders, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.

Anastasia Skouma (A)

Institute of Child Health, Aghia Sophia Children's Hospital, Thivon & Papadiamantopoulou, 11527, Athens, Greece.

Karolina M Stepien (KM)

Adult Inherited Metabolic Disorders Department, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, Greater Manchester, UK.

David J Timson (DJ)

School of Pharmacy and Biomolecular Sciences, University of Brighton, Huxley Building, Lewes Road, Brighton, BN2 4GJ, UK.

Gerard T Berry (GT)

Division of Genetics and Genomics, Harvard Medical School, Boston Children's Hospital, 3 Blackfan Circle, Center for Life Science Building, Suite 14070, Boston, MA, 02115, USA.

M Estela Rubio-Gozalbo (ME)

Department of Pediatrics and Clinical Genetics, Maastricht University Medical Centre+, P. Debyelaan 25, P.O. Box 5800, 6229 HX, Maastricht, The Netherlands. estela.rubio@mumc.nl.
GROW, Maastricht University, Maastricht, The Netherlands. estela.rubio@mumc.nl.
MetabERN: European Reference Network for Hereditary Metabolic Disorders, Udine, Italy. estela.rubio@mumc.nl.
UMD: United for Metabolic Diseases Member, Amsterdam, The Netherlands. estela.rubio@mumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH